Medication responsiveness of motor symptoms in a population-based study of Parkinson disease.
Medication responsiveness of motor symptoms in a population-based study of Parkinson disease.
复制标题
DOI：
10.4061/2011/967839
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Vickrey BG
中科院分区：
文献类型：
--
作者：
Bordelon YM;Hays RD;Vassar SD;Diaz N;Bronstein J;Vickrey BG
在加利福尼亚州中部进行的一项基于人群的研究中，我们评估了帕金森病患者服用药物后运动症状改善的程度。在停药和服药两种状态下对受试者进行统一的帕金森病评定量表(UPDRS)的运动部分，并将这些分数之间的差异作为症状改善的指标。得分较高的负分数与更严重的基线症状相关。根据使用的药物类别划分的受试者的运动UPDRS评分也有相同的改善：左旋多巴单独7.3分，左旋多巴加其他药物8.5分，多巴胺激动剂但不左旋多巴6.1分。此外，当受试者按帕金森病亚型划分时，改善的程度没有差别，定义为震颤为主、僵硬运动迟缓或混合。在这个以社区为基础的样本中，这些值在先前研究定义的临床重要差异的范围内。
We assessed degree of Parkinson disease motor symptom improvement with medication among subjects enrolled in an ongoing, population-based study in Central California. The motor section of the unified Parkinson disease rating scale (UPDRS) was performed on subjects in both OFF and ON medication states, and difference between these scores was used as an indicator of symptomatic benefit. Higher OFF minus ON scores correlated with more severe baseline symptoms. There was equivalent improvement on the motor UPDRS scale for subjects divided according to medication classes used: levodopa alone 7.3 points, levodopa plus other medications 8.5 points, and dopamine agonists but not levodopa 6.1 points. In addition, there was no difference in the magnitude of improvement when subjects were divided according to Parkinson disease subtype, defined as tremor dominant, akinetic-rigid, or mixed. In this community-based sample, these values are within the range of a clinically important difference as defined by previous studies.
登录
查看更多内容
影响因子：
--
作者：
Josephs, KA;Matsumoto, JY;Ahlskog, JE
通讯作者：
Ahlskog, JE
影响因子：
9.9
作者：
NUTT, JG;WOODWARD, WR
通讯作者：
WOODWARD, WR
影响因子：
8.6
作者：
Kang, GA;Bronstein, JM;Ritz, B
通讯作者：
Ritz, B
影响因子：
9.9
作者：
Rajput, A. H.;Voll, A.;Rajput, A.
通讯作者：
Rajput, A.
影响因子：
--
作者：
Shulman, Lisa M.;Gruber-Baldini, Ann L.;Weiner, William J.
通讯作者：
Weiner, William J.